Literature DB >> 15930317

Hsp70-like protein 1 fusion protein enhances induction of carcinoembryonic antigen-specific CD8+ CTL response by dendritic cell vaccine.

Yanfeng Wu1, Tao Wan, Xiangyang Zhou, Baomei Wang, Feng Yang, Nan Li, Guoyou Chen, Shengming Dai, Shuxun Liu, Minghui Zhang, Xuetao Cao.   

Abstract

Heat shock proteins (HSP) have been revealed to interact with antigen-presenting cells and have potent adjuvant capability to induce antigen-specific CD8+ CTL and Th1 responses. Our previous work shows how Hsp70-like protein 1 (Hsp70L1), as a new member of the Hsp70 subfamily, acts as potent Th1 adjuvant. Here, we report the efficient induction of tumor antigen-specific immune response by dendritic cells pulsed with recombinant fusion protein of Hsp70L1 and CEA(576-669) fragment of the carcinoembryonic antigen (CEA) containing CAP-1 (a HLA-A2-restricted CTL epitope). Fusion protein CEA(576-669)-Hsp70L1 can promote dendritic cell maturation and activate dendritic cells to produce cytokines, such as interleukin-12, interleukin-1beta, and tumor necrosis factor-alpha, and chemokines, such as macrophage inflammatory protein-1alpha, macrophage inflammatory protein-1beta, and regulated on activation, normal T expressed and secreted, indicating the adjuvant ability of Hsp70L1 in the fusion protein. CEA-specific HLA-A2.1-restricted CD8+ CTLs either from patients with CEA+/HLA-A2.1+ colon carcinoma or from splenocytes of immunized HLA-A2.1/Kb transgenic mice can be generated more efficiently after stimulations or immunizations with dendritic cells pulsed by CEA(576-669)-Hsp70L1 than with dendritic cells pulsed by CEA(576-669) alone, resulting in secreting more Th1 cytokine IFN-gamma and killing target cells more potently in an antigen-specific and HLA-A2.1-restricted manner. Adoptive transfer of splenocytes from transgenic mice immunized with CEA(576-669)-Hsp70L1-pulsed dendritic cells can inhibit tumor growth and prolong survival in nude mice bearing CEA+/HLA-A2.1+ human colon carcinoma more markedly. Therefore, Hsp70L1 has potent adjuvant effect in form of fusion protein, indicating that Hsp70L1 may be widely used as Th1 adjuvant to prepare antigenic fusion protein for the therapeutics of cancer or infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15930317     DOI: 10.1158/0008-5472.CAN-04-3912

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  Evidence from case-control and longitudinal studies supports associations of genetic variation in APOE, CETP, and IL6 with human longevity.

Authors:  Mette Soerensen; Serena Dato; Qihua Tan; Mikael Thinggaard; Rabea Kleindorp; Marian Beekman; H Eka D Suchiman; Rune Jacobsen; Matt McGue; Tinna Stevnsner; Vilhelm A Bohr; Anton J M de Craen; Rudi G J Westendorp; Stefan Schreiber; P Eline Slagboom; Almut Nebel; James W Vaupel; Kaare Christensen; Lene Christiansen
Journal:  Age (Dordr)       Date:  2012-01-12

Review 2.  Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine.

Authors:  Hongmei Xu; Xuetao Cao
Journal:  Front Med       Date:  2011-12       Impact factor: 4.592

3.  Toll-like receptor 4 (TLR4) is essential for Hsp70-like protein 1 (HSP70L1) to activate dendritic cells and induce Th1 response.

Authors:  Hongliang Fang; Yanfeng Wu; Xiaohui Huang; Wenying Wang; Bing Ang; Xuetao Cao; Tao Wan
Journal:  J Biol Chem       Date:  2011-07-05       Impact factor: 5.157

4.  Targeting hepatitis B virus antigens to dendritic cells by heat shock protein to improve DNA vaccine potency.

Authors:  Qin-Long Gu; Xue Huang; Wen-Hong Ren; Lei Shen; Bing-Ya Liu; Si-Yi Chen
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

Review 5.  Immunotherapy and immunoescape in colorectal cancer.

Authors:  Guillermo Mazzolini; Oihana Murillo; Catalina Atorrasagasti; Juan Dubrot; Iñigo Tirapu; Miguel Rizzo; Ainhoa Arina; Carlos Alfaro; Arantza Azpilicueta; Carmen Berasain; José L Perez-Gracia; Alvaro Gonzalez; Ignacio Melero
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

Review 6.  TAA polyepitope DNA-based vaccines: a potential tool for cancer therapy.

Authors:  Roberto Bei; Antonio Scardino
Journal:  J Biomed Biotechnol       Date:  2010-06-17

7.  A modified HLA-A*0201-restricted CTL epitope from human oncoprotein (hPEBP4) induces more efficient antitumor responses.

Authors:  Weihong Sun; Junyi Shi; Jian Wu; Junchu Zhang; Huabiao Chen; Yuanyuan Li; Shuxun Liu; Yanfeng Wu; Zhigang Tian; Xuetao Cao; Nan Li
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

8.  HSP70L1-mediated intracellular priming of dendritic cell vaccination induces more potent CTL response against cancer.

Authors:  Shuxun Liu; Lin Yi; Ma Ling; Jinxia Jiang; Lijun Song; Juan Liu; Xuetao Cao
Journal:  Cell Mol Immunol       Date:  2016-06-27       Impact factor: 11.530

9.  TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells.

Authors:  Hongliang Fang; Bing Ang; Xinyun Xu; Xiaohui Huang; Yanfeng Wu; Yanping Sun; Wenying Wang; Nan Li; Xuetao Cao; Tao Wan
Journal:  Cell Mol Immunol       Date:  2013-12-23       Impact factor: 11.530

10.  Caveolin-1 Promotes the Imbalance of Th17/Treg in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Nina Sun; Xiaofang Wei; Jingluan Wang; Zhaozhong Cheng; Weihong Sun
Journal:  Inflammation       Date:  2016-12       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.